Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 373

1.

Impact of antiretroviral therapy on opportunistic infections of HIV-infected children in the therapeutic research, education and AIDS training asia pediatric HIV observational database.

Prasitsuebsai W, Kariminia A, Puthanakit T, Lumbiganon P, Hansudewechakul R, Siew Moy F, Law M, Kumarasamy N, Razali K, Sirisanthana V, Sohn AH, Chokephaibulkit K.

Pediatr Infect Dis J. 2014 Jul;33(7):747-52. doi: 10.1097/INF.0000000000000226.

2.

Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR 3rd; Pediatric AIDS Clincial Trials Group Protocol 219C Team.

Arch Pediatr Adolesc Med. 2006 Aug;160(8):778-87.

PMID:
16894075
3.

Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.

Dankner WM, Lindsey JC, Levin MJ; Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327.

Pediatr Infect Dis J. 2001 Jan;20(1):40-8.

PMID:
11176565
4.

Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: temporal trends and relation to CD4 count.

De Beaudrap P, Boullé C, Lewden C, Gabillard D, Nacro B, Diagbouga S, Fassinou P, Hien H, Laurent C, Msellati P; ANRS 12222 Morbidity/Mortality Study Group.

Pediatr Infect Dis J. 2013 Apr;32(4):354-60. doi: 10.1097/INF.0b013e318278b222.

PMID:
23099424
5.

The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.

Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, Rathore M, Read JS, Huang S, Elgie C, Hudgens K, Hughes W.

Pediatrics. 2005 Apr;115(4):e488-94. Epub 2005 Mar 16.

PMID:
15772172
6.

Incidence of opportunistic and other infections in HIV-infected children in the HAART era.

Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, Seage GR 3rd.

JAMA. 2006 Jul 19;296(3):292-300.

PMID:
16849662
7.

Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, Havens P, Nesheim S, Read JS, Serchuck L, Van Dyke R; Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America; Pediatric Infectious Diseases Society; American Academy of Pediatrics.

MMWR Recomm Rep. 2009 Sep 4;58(RR-11):1-166.

8.

Incidence and associated factors of pulmonary tuberculosis in HIV-infected children after highly active antiretroviral therapy (HAART) in China: a retrospective study.

Mu W, Zhao Y, Sun X, Ma Y, Yu L, Liu X, Zhao D, Dou Z, Fang H, Zhang F.

AIDS Care. 2014;26(9):1127-35. doi: 10.1080/09540121.2014.882492. Epub 2014 Feb 10.

PMID:
24512621
9.

Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era.

Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, Van Dyke RB; Pediatric AIDS Clinical Trials Group219/219C Team.

J Acquir Immune Defic Syndr. 2010 Jan;53(1):86-94. doi: 10.1097/QAI.0b013e3181b9869f.

10.

Incidence of opportunistic illness before and after initiation of highly active antiretroviral therapy in children.

Nesheim SR, Hardnett F, Wheeling JT, Siberry GK, Paul ME, Emmanuel P, Bohannon B, Dominguez K; LEGACY Consortium.

Pediatr Infect Dis J. 2013 Oct;32(10):1089-95. doi: 10.1097/INF.0b013e31829ee893.

11.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
12.

Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso.

Dembélé M, Saleri N, Carvalho AC, Saouadogo T, Hien AD, Zabsonre I, Koala ST, Simporé J, Matteelli A.

Int J Tuberc Lung Dis. 2010 Mar;14(3):318-23.

PMID:
20132623
13.

Incidence and predictors of severe anemia in Asian HIV-infected children using first-line antiretroviral therapy.

Bunupuradah T, Kariminia A, Chan KC, Ramautarsing R, Huy BV, Han N, Nallusamy R, Hansudewechakul R, Saphonn V, Sirisanthana V, Chokephaibulkit K, Kurniati N, Kumarasamy N, Yusoff NK, Razali K, Fong SM, Sohn AH, Lumbiganon P; TREAT Asia Pediatric HIV Observational Database.

Int J Infect Dis. 2013 Oct;17(10):e806-10. doi: 10.1016/j.ijid.2013.04.006. Epub 2013 Jun 10.

14.

Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy.

Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjananit S, Wannarit P, Sirisanthana T, Sirisanthana V.

Clin Infect Dis. 2007 Feb 15;44(4):599-604. Epub 2007 Jan 9.

15.

Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.

Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, Farley J, Palumbo P, Koenig LJ, Bulterys M.

Pediatrics. 2007 Jul;120(1):100-9.

PMID:
17606567
16.

Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database.

Hansudewechakul R, Sirisanthana V, Kurniati N, Puthanakit T, Lumbiganon P, Saphonn V, Yusoff NK, Kumarasamy N, Fong SM, Nallusamy R, Srasuebkul P, Law M, Sohn AH, Chokephaibulkit K; TREAT Asia Pediatric HIV Observational Database.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):503-9. doi: 10.1097/QAI.0b013e3181f5379a.

17.

The clinical burden of tuberculosis among human immunodeficiency virus-infected children in Western Kenya and the impact of combination antiretroviral treatment.

Braitstein P, Nyandiko W, Vreeman R, Wools-Kaloustian K, Sang E, Musick B, Sidle J, Yiannoutsos C, Ayaya S, Carter EJ.

Pediatr Infect Dis J. 2009 Jul;28(7):626-32. doi: 10.1097/INF.0b013e31819665c5.

PMID:
19451858
18.

Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan.

Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X.

Am J Respir Crit Care Med. 2005 Jul 1;172(1):123-7. Epub 2005 Apr 1.

PMID:
15805184
19.

Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.

Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC.

AIDS. 2003 Dec 5;17(18):2615-22.

PMID:
14685055
20.

Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006).

Guillén S, García San Miguel L, Resino S, Bellón JM, González I, Jiménez de Ory S, Muñoz-Fernández MA, Navarro ML, Gurbindo MD, de José MI, Mellado MJ, Martín-Fontelos P, Gonzalez-Tomé MI, Martinez J, Beceiro J, Roa MA, Ramos JT; Madrid Group for Research on Pediatric HIV Infection.

HIV Med. 2010 Apr;11(4):245-52. doi: 10.1111/j.1468-1293.2009.00768.x. Epub 2009 Dec 28.

Supplemental Content

Support Center